 |
|
Aminocaproic AcidUse in Control of Hemorrhage in Patients With Amegakaryocytic Thrombocytopenia
Frank H. Gardner, MD;
Richard E. Helmer III, MD
JAMA. 1980;243(1):35-37.
Abstract
| |
The bleeding complications of some forms of thrombocytopenia are difficult to control. Many patients become refractory to platelet transfusions even when HLA-matched. We have successfully used aminocaproic acid to control bleeding in 13 patients with amegakaryocytic thrombocytopenia. Four patients receiving long-term therapy with this drug had striking reductions in the number of platelet transfusions required for capillary bleeding. No adverse effects have been noted save for orthostatic hypotension, which is ameliorated by a reduction in dosage. Quantitative platelet function changes have been impossible to demonstrate, but no changes were noted in four patients with normal platelet counts who were receiving high-dose aminocaproic acid for treatment of subarachnoid hemorrhage. Aminocaproic acid has proved to be a valuable agent in the management of patients with amegakaryocytic thrombocytopenia, especially in decreasing the need for platelet transfusions.
(JAMA 243:35-37, 1980)
Author Affiliations
From the Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Medical Branch, Galveston.
Footnotes
Reprint requests to Division of Hematology-Oncology, Room MW 404, John Sealy Hospital, University of Texas Medical Branch, Galveston, TX 77550 (Dr Gardner).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Hemostatic Drugs
Mannucci
NEJM 1998;339:245-253.
FULL TEXT
Control of Bleeding in Patients With Immune and Nonimmune Thrombocytopenia With Aminocaproic Acid
Bartholomew et al.
Arch Intern Med 1989;149:1959-1961.
ABSTRACT
|
